Showing results (111-120 of 715) with videos related to
Sort By:
Pageof 72
Seminars in Hematology|February 13, 2007
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistanceElias Jabbour, Jorge Cortes, Susan O'Brien, et al.Seminars in Hematology|November 20, 2013
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemiaElias Jabbour, Jorge Cortes, Farhad Ravandi, et al.Expert Opinion on Investigational Drugs|April 23, 2014
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaNaveen Pemmaraju, Hagop Kantarjian, Michael Andreeff, et al.Clinical Lymphoma, Myeloma & Leukemia|November 6, 2012
Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibodyPaolo Strati, Jorge Cortes, Stefan Faderl, et al.Cancer|June 19, 2012
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008Yiming Chen, Hagop Kantarjian, Haijun Wang, et al.Cancer|February 2, 2010
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phaseHagop M Kantarjian, Jorge Cortes, Paul La Rosée, et al.Expert Opinion on Pharmacotherapy|March 21, 2012
Treatment options for chronic myeloid leukemiaMaria Florencia Tanaka, Hagop Kantarjian, Jorge Cortes, et al.Current Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemiaFabio P S Santos, Hagop Kantarjian, Jorge Cortes, et al.Cancer|November 25, 2003
Imatinib mesylate causes hypopigmentation in the skinAnne S Tsao, Hagop Kantarjian, Jorge Cortes, et al.Leukemia & Lymphoma|January 3, 2013
Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosisAlfonso Quintás-Cardama, Matjaz Sever, Jorge Cortes, et al.Pageof 72